
Although there are some similarities between the way that US and European authorities uphold antibody patents, there are also some important differences.
Juliet Redhouse is a managing associate at Mathys & Squire LLP. She handles a wide range of subject matter in the fields of molecular biology, pharmaceuticals, and biotechnology and has particular experience in the areas of antibody technology, vaccine technology, protein- and peptide-based medicines, recombinant gene expression, diagnostic assays, and medical devices.
Published: September 1st 2018 | Updated: